E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Bioactive Compounds from Marine Sponges"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 30 November 2018

Special Issue Editor

Guest Editor
Dr. RuAngelie Edrada-Ebel

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, The John Arbuthnott Building, 161 Cathedral Street, Glasgow G4 0RE, UK
Website | E-Mail
Fax: +44 141 552 2562
Interests: natural products; drug discovery; NMR spectroscopy; metabolomics

Special Issue Information

Dear Colleagues,

In the past few decades, marine natural product research has focused a great deal on sponges. Recently, the number of scientific papers on microbial natural products derived from sponges have been increasing. Although new sources are being explored for collecting sponges for the search of novel compounds for new drugs, there is also an increasing awareness in protecting the environment. Marine natural products scientists have gone through a more ecological and sustainable way to source novel bioactive compounds from sponges. This led scientists to focus more on bioactive secondary metabolites from sponge-derived microorganisms. In the past, it has also been questioned who was the main producer of these unique natural products, considering their structural similarity with microbial metabolites.

In this Special Issue, we would like to revisit the current researches done on bioactive compounds from marine sponges. However, with the current trends in marine natural products research, we would also like to highlight bioactive compounds isolated from sponge-derived microorganisms. I would like to invite colleagues to submit articles on their current research on bioactive compounds from marine sponges, as well as secondary metabolites from sponge-derived or -associated microorganisms.

Dr. RuAngelie Edrada-Ebel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine sponges
  • sponge-derived microbes
  • bioactive marine natural products

Published Papers (6 papers)

View options order results:
result details:
Displaying articles 1-6
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle New Sulfur-Containing Polyarsenicals from the New Caledonian Sponge Echinochalina bargibanti
Mar. Drugs 2018, 16(10), 382; https://doi.org/10.3390/md16100382
Received: 14 September 2018 / Revised: 3 October 2018 / Accepted: 9 October 2018 / Published: 11 October 2018
PDF Full-text (952 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Arsenicin A (C3H6As4O3) was isolated from the New Caledonian poecilosclerid sponge Echinochalina bargibanti, and described as the first natural organic polyarsenic compound. Further bioguided fractionation of the extracts of this sponge led us to
[...] Read more.
Arsenicin A (C3H6As4O3) was isolated from the New Caledonian poecilosclerid sponge Echinochalina bargibanti, and described as the first natural organic polyarsenic compound. Further bioguided fractionation of the extracts of this sponge led us to isolate the first sulfur-containing organic polyarsenicals ever found in Nature. These metabolites, called arsenicin B and arsenicin C, are built on a noradamantane-type framework that is characterized by an unusual As–As bonding. Extensive NMR measurements, in combination with mass spectra, enabled the assignment of the structure for arsenicin B (C3H6As4S2) as 2. The scarcity of arsenicin C and its intrinsic chemical instability only allowed the collection of partial spectral data, which prevented the full structural definition. After the extensive computational testing of several putative structures, structure 3 was inferred for arsenicin C (C3H6As4OS) by comparing the experimental and density functional theory (DFT)-calculated 1H and 13C NMR spectra. Finally, the absolute configurations of 2 and 3 were determined with a combined use of experimental and time-dependent (TD)-DFT calculated electronic circular dichroism (ECD) spectra and observed specific rotations. These findings pose great challenges for the investigation of the biosynthesis of these metabolites and the cycle of arsenic in Nature. Arsenicins B and C showed strong antimicrobial activities, especially against S. aureus, which is comparable to the reference compound gentamycin. Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
Figures

Graphical abstract

Open AccessArticle Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells
Mar. Drugs 2018, 16(10), 361; https://doi.org/10.3390/md16100361
Received: 11 September 2018 / Revised: 24 September 2018 / Accepted: 29 September 2018 / Published: 1 October 2018
PDF Full-text (5198 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Triple negative breast cancer (TNBC) is a subtype of breast cancers that currently lacks effective targeted therapy. In this study, we found that aurantoside C (C828), isolated from the marine sponge Manihinea lynbeazleyae collected from Western Australia, exhibited higher cytotoxic activities in TNBC
[...] Read more.
Triple negative breast cancer (TNBC) is a subtype of breast cancers that currently lacks effective targeted therapy. In this study, we found that aurantoside C (C828), isolated from the marine sponge Manihinea lynbeazleyae collected from Western Australia, exhibited higher cytotoxic activities in TNBC cells compared with non-TNBC (luminal and normal-like) cells. The cytotoxic effect of C828 was associated to the accumulation of cell at S-phase, resulting in the decline of cyclin D1, cyclin E1, CDK4, and CDK6, and an increase in p21. We also found that C828 inhibited the phosphorylation of Akt/mTOR and NF-kB pathways and increased the phosphorylation of p38 MAPK and SAPK/JNK pathways, leading to apoptosis in TNBC cells. These effects of C828 were not observed in non-TNBC cells at the concentrations that were cytotoxic to TNBC cells. When compared to the cytotoxic effect with the chemotherapeutic drugs doxorubicin and cisplatin, C828 was found to be 20 times and 35 times more potent than doxorubicin and cisplatin, respectively. These results indicate that C828 could be a promising lead for developing new anticancer agents that target TNBC cells. Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
Figures

Figure 1

Open AccessArticle Sesterterpenoid and Steroid Metabolites from a Deep-Water Alaska Sponge Inhibit Wnt/β-Catenin Signaling in Colon Cancer Cells
Mar. Drugs 2018, 16(9), 297; https://doi.org/10.3390/md16090297
Received: 18 July 2018 / Revised: 1 August 2018 / Accepted: 23 August 2018 / Published: 27 August 2018
PDF Full-text (3105 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
The Wnt/β-catenin signaling pathway is known to play critical roles in a wide range of cellular processes: cell proliferation, differentiation, migration and embryonic development. Importantly, dysregulation of this pathway is tightly associated with pathogenesis in most human cancers. Therefore, the Wnt/β-catenin pathway has
[...] Read more.
The Wnt/β-catenin signaling pathway is known to play critical roles in a wide range of cellular processes: cell proliferation, differentiation, migration and embryonic development. Importantly, dysregulation of this pathway is tightly associated with pathogenesis in most human cancers. Therefore, the Wnt/β-catenin pathway has emerged as a promising target in anticancer drug screening programs. In the present study, we have isolated three previously unreported metabolites from an undescribed sponge, a species of Monanchora (Order Poecilosclerida, Family Crambidae), closely related to the northeastern Pacific species Monanchora pulchra, collected from deep waters off the Aleutian Islands of Alaska. Through an assortment of NMR, MS, ECD, computational chemical shifts calculation, and DP4, chemical structures of these metabolites have been characterized as spirocyclic ring-containing sesterterpenoid (1) and cholestane-type steroidal analogues (2 and 3). These compounds exhibited the inhibition of β-catenin response transcription (CRT) through the promotion of β-catenin degradation, which was in part implicated in the antiproliferative activity against two CRT-positive colon cancer cell lines. Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
Figures

Figure 1

Open AccessArticle Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells
Mar. Drugs 2018, 16(2), 53; https://doi.org/10.3390/md16020053
Received: 7 December 2017 / Revised: 22 January 2018 / Accepted: 31 January 2018 / Published: 8 February 2018
Cited by 1 | PDF Full-text (5913 KB) | HTML Full-text | XML Full-text | Supplementary Files
Abstract
Triple negative breast cancer (TNBC) is currently the only group of breast cancers without an effective targeted therapy. Marine sponges have historically been a source of compounds with anticancer activity. In this study, we screened extracts from twenty marine sponges collected off the
[...] Read more.
Triple negative breast cancer (TNBC) is currently the only group of breast cancers without an effective targeted therapy. Marine sponges have historically been a source of compounds with anticancer activity. In this study, we screened extracts from twenty marine sponges collected off the coast of Western Australia for cytotoxic activity against TNBC cells. One very active extract derived from the sponge Monanchora viridis was selected for bioactivity-guided fractionation. Through multiple steps of purification, we isolated a potent cytotoxic compound, which was identified as crambescidin 800 (C800). We found that C800 exhibited cytotoxic potency in a panel of breast cancer cells, of which TNBC and luminal cancer cell models were the most sensitive. In addition, C800 induced cell cycle arrest at the G2/M phase, resulting in a decline in the expression of cyclin D1, CDK4, and CDK6 in TNBC cells. This effect was associated with the inhibition of phosphorylation of Akt, NF-κB, and MAPK pathways, resulting in apoptosis in TNBC cells. Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
Figures

Graphical abstract

Review

Jump to: Research

Open AccessReview Chemistry and Biological Activities of the Marine Sponges of the Genera Mycale (Arenochalina), Biemna and Clathria
Mar. Drugs 2018, 16(6), 214; https://doi.org/10.3390/md16060214
Received: 28 April 2018 / Revised: 7 June 2018 / Accepted: 13 June 2018 / Published: 18 June 2018
PDF Full-text (8813 KB) | HTML Full-text | XML Full-text
Abstract
Over the past seven decades, particularly since the discovery of the first marine-derived nucleosides, spongothymidine and spongouridine, from the Caribbean sponge Cryptotethya crypta in the early 1950s, marine natural products have emerged as unique, renewable and yet under-investigated pools for discovery of new
[...] Read more.
Over the past seven decades, particularly since the discovery of the first marine-derived nucleosides, spongothymidine and spongouridine, from the Caribbean sponge Cryptotethya crypta in the early 1950s, marine natural products have emerged as unique, renewable and yet under-investigated pools for discovery of new drug leads with distinct structural features, and myriad interesting biological activities. Marine sponges are the most primitive and simplest multicellular animals, with approximately 8900 known described species, although more than 15,000 species are thought to exist worldwide today. These marine organisms potentially represent the richest pipeline for novel drug leads. Mycale (Arenochalina) and Clathria are recognized marine sponge genera belonging to the order Poecilosclerida, whereas Biemna was more recently reclassified, based on molecular genetics, as a new order Biemnida. Together, these sponge genera contribute to the production of physiologically active molecular entities with diverse structural features and a wide range of medicinal and therapeutic potentialities. In this review, we provide a comprehensive insight and up-to-date literature survey over the period of 1976–2018, focusing on the chemistry of the isolated compounds from members of these three genera, as well as their biological and pharmacological activities, whenever available. Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
Figures

Graphical abstract

Open AccessReview Bioactive Secondary Metabolites from the Marine Sponge Genus Agelas
Mar. Drugs 2017, 15(11), 351; https://doi.org/10.3390/md15110351
Received: 19 September 2017 / Revised: 25 October 2017 / Accepted: 3 November 2017 / Published: 8 November 2017
Cited by 2 | PDF Full-text (7740 KB) | HTML Full-text | XML Full-text
Abstract
The marine sponge genus Agelas comprises a rich reservoir of species and natural products with diverse chemical structures and biological properties with potential application in new drug development. This review for the first time summarized secondary metabolites from Agelas sponges discovered in the
[...] Read more.
The marine sponge genus Agelas comprises a rich reservoir of species and natural products with diverse chemical structures and biological properties with potential application in new drug development. This review for the first time summarized secondary metabolites from Agelas sponges discovered in the past 47 years together with their bioactive effects. Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
Figures

Figure 1

Back to Top